Donna Dalorson: A New Hope for HAE

This chapter discusses the investigational drug Donna Dalorson for treating hereditary angioedema, focusing on its mechanisms and the promising results of a phase three clinical trial. The effectiveness of the treatment in reducing attacks and improving patients' quality of life, along with considerations of adverse events, are also explored.